US Edition
News from Queens Chronicle
We’ve assigned a media bias rating of Lean Left to Queens Chronicle. You can read more about our methodology here.
If you want to know if Queens Chronicle is credible or reliable, look no further. We rank Queens Chronicle as High factuality. Find out more about our methodology here.
Information about Queens Chronicle
Where is Queens Chronicle located?Queens Chronicle's WebsiteQueens Chronicle's TwitterQueens Chronicle's WikipediaMedia Bias Ratings
Average Bias Rating:
Lean Left
Lean Left
byMedia Bias/Fact CheckDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top Queens Chronicle News
Hicksville · HicksvilleHICKSVILLE, N.Y., Oct. 17, 2025 /PRNewswire/ -- Flagstar Bank, N.A. (NYSE: FLG) today announced the completion of its previously approved holding company reorganization, effective at the close of business on October 17, 2025, a step that simplifies the corporate structure,…See the Story
FLAGSTAR BANK, N.A. ANNOUNCES COMPLETION OF HOLDING COMPANY REORGANIZATION
58% Center coverage: 17 sources
United States · United StatesRybelsus® (semaglutide) tablets 7 mg or 14 mg, the only FDA-approved oral GLP-1 medicine available, now indicated to reduce the risk of major adverse cardiovascular events (MACE) such as CV death, heart attack, or stroke in adults with type 2…See the Story
FDA approves Novo Nordisk's oral semaglutide for cardiovascular (CV) risk reduction in adults with type 2 diabetes who are at high risk, including those who have not had a prior CV event
53% Center coverage: 15 sources
Singapore, Singapore · SingaporeSINGAPORE, Oct. 18, 2025 /PRNewswire/ -- SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company developing next-generation immunotherapies for infectious diseases and their associated cancers, announced the presentation ofSee the Story
SCG announces presentation of clinical results of SCG142 in patients with HPV-related carcinoma at ESMO 2025
46% Left coverage: 11 sources
